These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 29303368)

  • 1. Imatinib for the treatment of hypereosinophilic syndromes.
    Helbig G
    Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
    Helbig G; Kyrcz-Krzemień S
    Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
    [No Abstract]   [Full Text] [Related]  

  • 3. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.
    Helbig G; Soja A; Świderska A; Hus M; Kyrcz-Krzemień S
    Leuk Lymphoma; 2016; 57(3):708-10. PubMed ID: 26430910
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
    Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
    Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
    Ng HJ; Tan DC; Yiu RC; How GF
    Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
    Li B; Zhang GS; Dai CW; Pei MF
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
    Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.
    Khoury P; Desmond R; Pabon A; Holland-Thomas N; Ware JM; Arthur DC; Kurlander R; Fay MP; Maric I; Klion AD
    Allergy; 2016 Jun; 71(6):803-10. PubMed ID: 26797802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
    La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
    Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.
    Qu SQ; Qin TJ; Xu ZF; Zhang Y; Ai XF; Li B; Zhang HL; Fang LW; Pan LJ; Hu NB; Xiao ZJ
    Oncotarget; 2016 May; 7(22):33229-36. PubMed ID: 27120808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
    Menif S; Ben Romdhane N; Hafsia R
    Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
    Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
    Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].
    Sekkach Y; Mekouar F; Jira M; Elqatni M; Elomri N; Fatihi J; Badaoui M; Hammi S; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
    Ann Pharm Fr; 2011 Sep; 69(5):277-81. PubMed ID: 21924129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene.
    García-Martínez P; Sitjas D; Llistosella E; Espinet B; Rodríguez-Rivera M; Hernandez-Muñoz M; Gallardo F; Pujol RM
    Acta Derm Venereol; 2017 Jul; 97(7):855-857. PubMed ID: 28374041
    [No Abstract]   [Full Text] [Related]  

  • 15. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
    Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
    Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
    Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
    Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature.
    Müller AM; Martens UM; Hofmann SC; Bruckner-Tuderman L; Mertelsmann R; Lübbert M
    Ann Hematol; 2006 Jan; 85(1):1-16. PubMed ID: 16136348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report.
    Yamamoto M; Ikuta K; Toki Y; Hatayama M; Shindo M; Torimoto Y; Okumura T
    Medicine (Baltimore); 2017 Sep; 96(36):e8001. PubMed ID: 28885361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypereosinophilic syndromes: current concepts and treatments.
    Gleich GJ; Leiferman KM
    Br J Haematol; 2009 May; 145(3):271-85. PubMed ID: 19243381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.